Revolution Medicines' Daraxonrasib Trial Reports 13.2-Month Median Survival in Pancreatic Cancer Patients
Revolution Medicines announced results from a late-stage trial of its experimental oral drug daraxonrasib for pancreatic cancer patients. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those on standard intravenous cytotoxic chemotherapy. The drug is administered as a once-daily pill.
France 24# Revolution Medicines Announces Positive Late-Stage Trial Results for Daraxonrasib Revolution Medicines announced on Monday the results of a late-stage trial for its experimental oral drug daraxonrasib in pancreatic cancer patients. The trial involved patients receiving daraxonrasib, which is administered as a once-daily pill. 2 months.
The trial compared daraxonrasib to intravenous cytotoxic chemotherapy, the standard of care for pancreatic cancer patients.
7 months. Revolution Medicines conducted the late-stage trial, as reported by the company.
Daraxonrasib targets pancreatic cancer through oral administration.
The trial focused on patients with pancreatic cancer, providing data on survival outcomes. Intravenous cytotoxic chemotherapy remains the established treatment option for such patients.
Medicines released the trial results on Monday.
The data indicate a difference in median overall survival between the two treatment groups. The company provided the details via its official channels.
